Neelakshi Mungra
YOU?
Author Swipe
View article: The Therapeutic Potential of Photoimmunotherapy as a Safe, Effective and Non‐Toxic Treatment Option for Superficial Triple Negative Breast Cancer
The Therapeutic Potential of Photoimmunotherapy as a Safe, Effective and Non‐Toxic Treatment Option for Superficial Triple Negative Breast Cancer Open
Triple‐negative breast cancer (TNBC) is the most aggressive breast cancer subtype, lacking estrogen (ER), progesterone (PR), and human epidermal growth factor receptor (HER‐2) expression. It disproportionately affects women of African desc…
View article: Machine learning and bioinformatic analyses link the cell surface receptor transcript levels to the drug response of breast cancer cells and drug off-target effects
Machine learning and bioinformatic analyses link the cell surface receptor transcript levels to the drug response of breast cancer cells and drug off-target effects Open
Breast cancer responds variably to anticancer therapies, often leading to significant off-target effects. This study proposes that the variability in tumour responses and drug-induced adverse events is linked to the transcriptional profile…
View article: CSPG4 as a target for the specific killing of triple-negative breast cancer cells by a recombinant SNAP-tag-based antibody-auristatin F drug conjugate
CSPG4 as a target for the specific killing of triple-negative breast cancer cells by a recombinant SNAP-tag-based antibody-auristatin F drug conjugate Open
Purpose Triple-negative breast cancer (TNBC) is phenotypic of breast tumors lacking expression of the estrogen receptor (ER), the progesterone receptor (PgR), and the human epidermal growth factor receptor 2 (HER2). The paucity of well-def…
View article: Click Chemistry-Generated Auristatin F–Linker–Benzylguanine for a SNAP-Tag-Based Recombinant Antibody–Drug Conjugate Demonstrating Selective Cytotoxicity toward EGFR-Overexpressing Tumor Cells
Click Chemistry-Generated Auristatin F–Linker–Benzylguanine for a SNAP-Tag-Based Recombinant Antibody–Drug Conjugate Demonstrating Selective Cytotoxicity toward EGFR-Overexpressing Tumor Cells Open
Antibody-drug conjugates (ADCs) are bifunctional molecules combining the targeting potential of monoclonal antibodies with the cancer-killing ability of cytotoxic drugs. This simple yet intelligently designed system directly addresses the …
View article: A Machine Learning and Bioinformatic Analysis Reveals an Associated between Cell Surface Receptor Transcript Levels with Drug Response of Breast Cancer Cells and the Drug Off-Target Effects
A Machine Learning and Bioinformatic Analysis Reveals an Associated between Cell Surface Receptor Transcript Levels with Drug Response of Breast Cancer Cells and the Drug Off-Target Effects Open
Breast cancer is characterised by varied responses to different anticancer therapies, which may provoke several different off-target effects. We hypothesise that for drugs that target cell surface receptors (CSRs), the different responses …
View article: Treatment of Chikungunya Virus (CHIKV) Using Targeted Immunotherapy
Treatment of Chikungunya Virus (CHIKV) Using Targeted Immunotherapy Open
Chikungunya virus (CHIKV) is the most common mosquito-borne Alphavirus infecting humans worldwide. Up to date, there are no antiviral treatments or vaccines approved to treat or prevent CHIKV for which treatments remain symptomatic based o…
View article: Recent advances in immunotherapies against infectious diseases
Recent advances in immunotherapies against infectious diseases Open
Summary Immunotherapies are disease management strategies that target or manipulate components of the immune system. Infectious diseases pose a significant threat to human health as evidenced by countries continuing to grapple with several…
View article: Advances in epidermal growth factor receptor specific immunotherapy: lessons to be learned from armed antibodies
Advances in epidermal growth factor receptor specific immunotherapy: lessons to be learned from armed antibodies Open
The epidermal growth factor receptor (EGFR) has been recognized as an important therapeutic target in oncology. It is commonly overexpressed in a variety of solid tumors and is critically involved in cell survival, proliferation, metastasi…
View article: Antibody-Based Immunotherapy: Alternative Approaches for the Treatment of Metastatic Melanoma
Antibody-Based Immunotherapy: Alternative Approaches for the Treatment of Metastatic Melanoma Open
Melanoma is the least common form of skin cancer and is associated with the highest mortality. Where melanoma is mostly unresponsive to conventional therapies (e.g., chemotherapy), BRAF inhibitor treatment has shown improved therapeutic ou…
View article: Targeted human cytolytic fusion proteins at the cutting edge: harnessing the apoptosis-inducing properties of human enzymes for the selective elimination of tumor cells
Targeted human cytolytic fusion proteins at the cutting edge: harnessing the apoptosis-inducing properties of human enzymes for the selective elimination of tumor cells Open
Patient-specific targeted therapy represents the holy grail of anti-cancer therapeutics, allowing potent tumor depletion without detrimental off-target toxicities. Disease-specific monoclonal antibodies have been employed to bind to oncoge…
View article: Human Granzyme B Based Targeted Cytolytic Fusion Proteins
Human Granzyme B Based Targeted Cytolytic Fusion Proteins Open
Cancer immunotherapy aims to selectively target and kill tumor cells whilst limiting the damage to healthy tissues. Controlled delivery of plant, bacterial and human toxins or enzymes has been shown to promote the induction of apoptosis in…
View article: CSPG4: A Target for Selective Delivery of Human Cytolytic Fusion Proteins and TRAIL
CSPG4: A Target for Selective Delivery of Human Cytolytic Fusion Proteins and TRAIL Open
Chondroitin-sulfate proteoglycan 4 (CSPG4) is a transmembrane glycoprotein overexpressed on malignant cells in several cancer types with only limited expression on normal cells. CSPG4 is implicated in several signaling pathways believed to…
View article: Human MAP Tau Based Targeted Cytolytic Fusion Proteins
Human MAP Tau Based Targeted Cytolytic Fusion Proteins Open
Some of the most promising small molecule toxins used to generate antibody drug conjugates (ADCs) include anti-mitotic agents (e.g., auristatin and its derivatives) which are designed to attack cancerous cells at their most vulnerable stat…
View article: Human MAP tau based targeted cytolytic fusion proteins
Human MAP tau based targeted cytolytic fusion proteins Open
Some of the most promising small molecule toxins used to generate antibody drug conjugates (ADCs) include anti-mitotic agents (e.g auristatin and its derivatives) which are designed to attack cancerous cells at their most vulnerable state …